KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Debt to Equity (2020 - 2025)

Regeneron Pharmaceuticals has reported Debt to Equity over the past 6 years, most recently at $0.06 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.06 for Q4 2025, down 6.02% from a year ago — trailing twelve months through Dec 2025 was $0.06 (down 6.02% YoY), and the annual figure for FY2025 was $0.06, down 6.02%.
  • Debt to Equity for Q4 2025 was $0.06 at Regeneron Pharmaceuticals, down from $0.06 in the prior quarter.
  • Over the last five years, Debt to Equity for REGN hit a ceiling of $0.17 in Q1 2021 and a floor of $0.06 in Q4 2025.
  • Median Debt to Equity over the past 5 years was $0.08 (2023), compared with a mean of $0.09.
  • Biggest five-year swings in Debt to Equity: crashed 41.29% in 2021 and later decreased 5.18% in 2025.
  • Regeneron Pharmaceuticals' Debt to Equity stood at $0.11 in 2021, then decreased by 17.13% to $0.09 in 2022, then dropped by 12.67% to $0.08 in 2023, then dropped by 11.45% to $0.07 in 2024, then fell by 6.02% to $0.06 in 2025.
  • The last three reported values for Debt to Equity were $0.06 (Q4 2025), $0.06 (Q3 2025), and $0.07 (Q2 2025) per Business Quant data.